Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $2.5 million.

  • Tango Therapeutics' Cash from Financing Activities rose 5.79% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 91.50%. This contributed to the annual value of $47.7 million for FY2024, which is 42.16% down from last year.
  • Tango Therapeutics' Cash from Financing Activities amounted to $2.5 million in Q3 2025, which was up 337.35% from $581,000 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Cash from Financing Activities ranged from a high of $327.8 million in Q3 2021 and a low of -$746,000 during Q2 2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $1.3 million (2024), whereas its average is $12.1 million.
  • As far as peak fluctuations go, Tango Therapeutics' Cash from Financing Activities tumbled by 3,081.02% in 2021, and later spiked by 70,944.25% in 2023.
  • Quarterly analysis of 5 years shows Tango Therapeutics' Cash from Financing Activities stood at -$120,000 in 2021, then soared by 539.17% to $527,000 in 2022, then surged by 178.37% to $1.5 million in 2023, then tumbled by 33.95% to $969,000 in 2024, then rose by 5.79% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $581,000 for Q2 2025, and $2,000 during Q1 2025.